Dry eye candidate update, cross-linking lead September cornea/external disease coverage
Click Here to Manage Email Alerts
Study results from a promising dry eye disease candidate and a blog about corneal cross-linking are two of the best-performing cornea/external disease items from September.
Read the top pieces of Healio/OSN coverage below.
Dry eye candidate demonstrates promising results in phase 2b study
AR-15512 achieved statistical significance for multiple sign and symptom endpoints in patients with dry eye disease, according to a press release from Aerie Pharmaceuticals. Read more.
NCX 4251 fails to meet primary, secondary endpoints in phase 2b blepharitis trial
NCX 4251 did not meet the primary or secondary efficacy endpoints in a phase 2b clinical trial investigating the ophthalmic suspension in patients with acute exacerbations of blepharitis, according to a press release from Nicox. Read more.
BLOG: Cost-effectiveness of cross-linking
As a cornea specialist, I have no doubt about the clinical value of cross-linking. Many patients and their families would say that no cost is too high to help preserve their vision and ocular health. Read more.
Glaukos, Attillaps enter licensing agreement for Demodex-targeting therapies
Glaukos and Attillaps Holdings have entered into a licensing agreement that grants Glaukos a global exclusive license to Attillaps’ library of proprietary investigational compounds targeting Demodex mites. Read more.
Surgical procedure shows long-term efficacy in the treatment of neurotrophic keratopathy
Corneal neurotization, a sensory nerve transplant procedure, can restore corneal sensation in insensate corneas and improve visual acuity. Read more.
Collapse
Read more about
Click Here to Manage Email Alerts